Cidara Therapeutics (CDTX) Short Interest Ratio & Short Volume → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free CDTX Stock Alerts $13.10 +0.05 (+0.38%) (As of 12:00 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Cidara Therapeutics Short Interest DataCurrent Short Volume8,200 sharesPrevious Short Volume195,400 sharesChange Vs. Previous Month-95.80%Dollar Volume Sold Short$135,250.80Short Interest Ratio / Days to Cover0.2Last Record DateApril 15, 2024Outstanding Shares4,562,000 sharesPercentage of Shares Shorted0.18%Today's Trading Volume10,690 sharesAverage Trading Volume51,529 sharesToday's Volume Vs. Average21% Short Selling Cidara Therapeutics ? Sign up to receive the latest short interest report for Cidara Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCDTX Short Interest Over TimeCDTX Days to Cover Over TimeCDTX Percentage of Float Shorted Over Time Ad InvestorPlaceProof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…Go here now for full story. Cidara Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20248,200 shares $135,250.80 -95.8%N/A0.2 $16.49 3/31/2024195,400 shares $179,768.00 +8.9%N/A0.3 $0.92 3/15/2024179,500 shares $122,939.55 -18.9%N/A0.3 $0.68 2/29/2024221,400 shares $156,640.50 -52.2%N/A0.3 $0.71 2/15/2024463,300 shares $320,742.59 -22.1%N/A0.7 $0.69 1/31/2024594,500 shares $381,193.40 -4.7%N/A0.9 $0.64 Get the Latest News and Ratings for CDTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024623,800 shares $477,830.80 -38.8%N/A1.1 $0.77 12/31/20231,020,000 shares $809,880.00 +44.3%N/A1.8 $0.79 12/15/2023707,100 shares $505,930.05 -23.6%N/A1.3 $0.72 11/30/2023925,600 shares $656,620.64 -24.8%N/A2.7 $0.71 11/15/20231,230,000 shares $953,250.00 -0.8%N/A2.8 $0.78 10/31/20231,240,000 shares $951,080.00 -6.1%N/A2.7 $0.77 10/15/20231,320,000 shares $1.21 million -12.0%N/A2.6 $0.92 9/30/20231,500,000 shares $1.41 million -3.9%N/A2.6 $0.94 9/15/20231,560,000 shares $1.67 million +31.1%N/A2.6 $1.07 8/31/20231,190,000 shares $933,079.00 -16.2%N/A1.8 $0.78 8/15/20231,420,000 shares $1.29 million -8.4%N/A2.3 $0.91 7/31/20231,550,000 shares $1.54 million -4.9%N/A1.8 $1.00 7/15/20231,630,000 shares $1.79 million -6.9%N/A1.7 $1.10 6/30/20231,750,000 shares $1.98 million +17.5%N/A1.6 $1.13 6/15/20231,490,000 shares $1.70 million -22.0%N/A0.8 $1.14 5/31/20231,910,000 shares $2.54 million -14.0%N/A0.7 $1.33 5/15/20232,220,000 shares $3.02 million -7.9%N/A0.7 $1.36 4/30/20232,410,000 shares $2.46 million -21.8%N/A0.8 $1.02 4/15/20233,080,000 shares $3.33 million -13.2%N/A0.9 $1.08 3/31/20233,550,000 shares $4.51 million +63.6%N/A1 $1.27 3/15/20232,170,000 shares $3.65 million -30.0%N/A0.7 $1.68 2/28/20233,100,000 shares $4.68 million +56.6%N/A1.6 $1.51 2/15/20231,980,000 shares $3.15 million +13.1%N/A1.4 $1.59 1/31/20231,750,000 shares $2.15 million +141.3%N/A1.4 $1.23 1/15/2023725,200 shares $957,264.00 +27.9%N/A1.2 $1.32 12/30/2022567,100 shares $428,897.73 -7.1%N/A1.8 $0.76 12/15/2022610,200 shares $305,038.98 +12.8%N/A2.2 $0.50 11/30/2022540,900 shares $346,230.09 -25.3%N/A2.2 $0.64 11/15/2022724,300 shares $452,542.64 +45.6%N/A3 $0.62 10/31/2022497,400 shares $305,901.00 +22.7%N/A1.9 $0.62 10/15/2022405,300 shares $226,886.94 -11.2%N/A0.9 $0.56 9/30/2022456,500 shares $286,682.00 -23.2%N/A1 $0.63 9/15/2022594,400 shares $428,740.72 -0.8%N/A1.2 $0.72 8/31/2022599,300 shares $407,524.00 +38.8%N/A1.2 $0.68Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. CDTX Short Interest - Frequently Asked Questions What is Cidara Therapeutics' current short interest? Short interest is the volume of Cidara Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 8,200 shares of CDTX short. Learn More on Cidara Therapeutics' current short interest. Which institutional investors are shorting Cidara Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cidara Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Cidara Therapeutics' short interest increasing or decreasing? Cidara Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 8,200 shares, a decline of 95.8% from the previous total of 195,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Cidara Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Cidara Therapeutics: Genenta Science S.p.A. (0.02%), Aligos Therapeutics, Inc. (0.87%), AVROBIO, Inc. (0.36%), Ikena Oncology, Inc. (5.48%), Turnstone Biologics Corp. (4.76%), Elutia Inc. (0.19%), Atara Biotherapeutics, Inc. (9.51%), Instil Bio, Inc. (0.23%), Precision BioSciences, Inc. (9.69%), Cognition Therapeutics, Inc. (0.73%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Cidara Therapeutics stock? Short selling CDTX is an investing strategy that aims to generate trading profit from Cidara Therapeutics as its price is falling. CDTX shares are trading down $0.39 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cidara Therapeutics? A short squeeze for Cidara Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CDTX, which in turn drives the price of the stock up even further. How often is Cidara Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CDTX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ENTX Short Interest GNTA Short Interest ALGS Short Interest AVRO Short Interest IKNA Short Interest TSBX Short Interest ELUT Short Interest ATRA Short Interest TIL Short Interest DTIL Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CDTX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford ClubObama’s Forever Term [exposed]Porter & Company